Source: Actinium Pharmaceuticals
Hillard Lazarus MD, Professor of Medicine at Case Western
Reserve University and Roland Turck MD, Radiopharmaceutical Veteran With
Extensive Drug Commercialization Experience to Be Featured Speakers
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)
("Actinium" or "the Company"), a biopharmaceutical Company developing
innovative targeted payload immunotherapeutics for the treatment of
advanced cancers, announced today that it will host a Key Opinion Leader
(KOL) Breakfast on Tuesday, May 12th, 2015 from 8:00 to 9:30 am Eastern
Time at the NY Palace Hotel (455 Madison Ave, Kennedy 1 Room, 4th
Floor). This event will be webcast during that time at http://lifesci.rampard.com/20150512.
The
meeting will feature bone marrow transplant and hematology specialist
Hillard M. Lazarus, MD, a Professor of Medicine at Case Western Reserve
University (CWRU) School of Medicine, as well as Disease Team Leader and
Director of Novel Cell Therapy at University Hospitals, Case Medical
Center, and Company Scientific Advisory Board Member. Also featured is
radiopharmaceutical industry veteran Roland U. Turck, MD, Managing
Partner at TurckBio and recently-appointed Senior Advisor to the
Actinium Board of Directors. Dr. Turck has extensive, unparalleled
experience in the launch and commercialization of radiopharmaceuticals.
Dr.
Lazarus performed the first bone marrow transplant in Ohio in 1976. His
seminal impact in multiple aspects of transplantation was recognized in
1986 with an invitation to develop and chair the Blood and Marrow
Transplant Committee of the National Cancer Institute, a position he
held until 2003. He now heads several clinical trials at the National
Center for Regenerative Medicine (CWRU). He has over 500 publications
and has won a variety of lifetime achievement, distinguished alumnus,
and cancer research awards, in addition to fellowships sponsored by the
Leukemia Society of America and the American Cancer Society.
Dr.
Turck was formerly the head of Bayer's Global Specialty Medicine
business, where he helped lead the commercialization of Xofigo, the
first alpha particle-emitting radioactive agent, whose launch has been
the most commercially successful of any radiopharmaceutical product to
date. He is an expert in biopharmaceutical specialty medicine with more
than 20 years of pharmaceutical industry experience at Bayer, Berlex,
and Schering. He boasts an extensive track record of developing and
commercializing several major oncology products on a global scale,
including Xofigo, Stivarga, Nexavar, and Campath.
Attendance at
the event is intended for institutional investors, sell-side analysts,
and investment bankers. If you wish to attend in person, please RSVP in
advance as space is limited, by contacting LifeSci Advisors at mac@lifesciadvisors.com. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20150512 for all interested parties. If you would like to ask a question during the live Q&A, please email your request to questions@lifesciadvisors.com.
About Bone Marrow Transplant:
Bone
marrow transplants (BMT) are most commonly used to treat leukemia and
lymphoma, conditions incurred when a blood or immune cell, respectively,
becomes cancerous and proliferates. Together, these diseases account
for some 50,000 to 75,000 new cases annually in the United States. BMT
involves first clearing a patient's body of his or her own immune cells
and then transplanting bone marrow, the source of all blood- and
immune-forming cells, from a tissue-matched donor. The new cells, which
are free of cancer, repopulate the patient's bone marrow and eventually
give rise to a functioning set of blood and immune cells, providing a
lifelong cure. BMT offers the chance of a "curative" outcome (2+ year
survival), and therefore can play a central role in the treatment of
AML. The impact of BMT on AML continues to increase with AML being the
most common and fastest growing indication for allogeneic BMT,
comprising 25% to 30% of all BMT recipients. There are currently over
100,000 BMT survivors across all indications and this number is expected
to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them
over age 60.
About Iomab-B
Iomab-B™ is
being developed to prepare patients for hematopoietic stem cell
transplantation (HSCT) and will enter a single, pivotal Phase 3 clinical
study in relapsed/refractory AML. Iomab-B is a radioimmunoconjugate
consisting of BC8, a novel murine monoclonal antibody, and iodine-131
radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research
Center to target CD45, a pan-leukocytic antigen widely expressed on
white blood cells. This antigen makes BC8 potentially useful in
targeting white blood cells in preparation for hematopoietic stem cell
transplantation in a number of blood cancer indications, including acute
myeloid leukemia (AML), chronic myeloid leukemia (CML), acute
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL),
Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma
(MM).
About Actimab-A
Actimab-A is a
radiolabeled antibody being developed for newly diagnosed AML in
patients over 60, and is currently in a multicenter Phase 1/2 clinical
trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform,
Actimab-A consists of the CD33 antibody lintuzumab linked to the
actinium-225 payload. Actimab-A has attracted support from leading
experts at the prestigious and high-volume cancer treatment hospitals
due to the potential of its safety and efficacy profile, as well as its
potential potency, specificity and ease of use. Clinical trials are
being conducted at world-class cancer institutions such as Memorial
Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins
Medicine, Columbia University Medical Center, University of Pennsylvania
Health System, Fred Hutchinson Cancer Research Center, and the Texas
Oncology-Baylor Charles A. Sammons Cancer Center. Actimab candidates are
in early development for other cancers.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy products are based on its
proprietary delivery platform for the therapeutic utilization of
alpha-emitting actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company's lead radiopharmaceutical product candidate Iomab-B is designed
to be used, upon approval, in preparing patients for hematopoietic stem
cell transplant, commonly referred to as bone marrow transplant. The
Company plans to conduct a single, pivotal, multicenter Phase 3 clinical
study of Iomab-B in refractory and relapsed AML patients over the age
of 55 with a primary endpoint of durable complete remission. The
Company's second product candidate, Actimab-A, is continuing its
clinical development in a Phase 1/2 trial for newly diagnosed AML
patients over the age of 60 in a single-arm multicenter trial.
No comments:
Post a Comment